Novacept gets $30 million for NovaSure launch:
This article was originally published in Clinica
Novacept, which has developed the NovaSure impedance controlled endometrial ablation system for the treatment of menorrhagia, has closed a $30 million round of venture financing. The Palo Alto, California company will use the funds for continued expansion of sales, marketing and deployment of the NovaSure device, which was approved by the FDA last autumn. The financing was led by Three Arch Partners and New Enterprise Associates.